Successful mobilization with AMD3100 and filgrastim with engraftment of autologous peripheral blood stem cells in a heavily pretreated pediatric patient with recurrent burkitt lymphoma

Pediatric Hematology and Oncology

Volumn 27, Issue 2, 2010, Pages 138-149

  Flatt, Terrie ^a   Lewing, Karen ^a   Gonzalez, Celia ^a   Anthony, Karen ^a   Ryan, Robin ^a   Jones, Ron ^a   Gamis, Alan ^a   Dalal, Jignesh ^a  

^a CHILDREN S MERCY HOSPITAL   (United States)

Author keywords

AMD3100 (Mozobil, Plerixafor); Aspergillosis; Burkitt lymphoma; Hematopoietic progenitor cell mobilization

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; CARBOPLATIN; CARMUSTINE; CASPOFUNGIN; CD34 ANTIGEN; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; ETOPOSIDE; IFOSFAMIDE; MELPHALAN; METHOTREXATE; PLERIXAFOR; PREDNISOLONE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RITUXIMAB; VINCRISTINE; VORICONAZOLE;

ABDOMINAL PAIN; ADOLESCENT; APHERESIS; ARTICLE; ASPERGILLOSIS; AUTOLOGOUS PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; BURKITT LYMPHOMA; CANCER REGRESSION; CANCER RELAPSE; CASE REPORT; CELL COUNT; CENTRAL NERVOUS SYSTEM TUMOR; DISEASE EXACERBATION; DRUG MEGADOSE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ENGRAFTMENT; EVENING DOSAGE; FATIGUE; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; MAXILLARY SINUS; MULTIPLE CYCLE TREATMENT; NAUSEA; PALATE; RECURRENT CANCER; STEM CELL MOBILIZATION;

ADOLESCENT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BURKITT LYMPHOMA; FEMALE; FILGRASTIM; HEMATOPOIETIC STEM CELL MOBILIZATION; HETEROCYCLIC COMPOUNDS; HUMANS; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; RECURRENCE; TREATMENT OUTCOME;

EID: 77749271185     PISSN: 08880018     EISSN: 15210669     Source Type: Journal    
DOI: 10.3109/08880010903447367     Document Type: Article

References (35)

1. Cottler-Fox MH, Lapidot T, Petit I, et al. Stem Cell Mobilization. Hematology 2003. ASH Education Program Book; 2003:419-438.
2. Cashen A, Lopez S, Gao F, et al. A phase II study of Plerixafor (AMD3100) plus G-SCF for autologous hematopoietic progenitor cell mobilization in patients with Hodgkin lymphoma. Biol Blood Marrow Transplant. 2008;14:1253-1261.
3. Ladenstein R, Pearce R, Hartmann O, et al. High-dose chemotherapy with autologous bone marrow rescue in children with poor-risk Burkitt's lymphoma: a report from the European Lymphoma Bone Marrow Transplantation Registry. Blood. 1997;90:2921-2930.
4. Griffin T, Weitzman S, Weinstein H, et al. A study of rituximab and ifosfamide, carboplatin, and etoposide chemotherapy in children with recurrent/refractory B-cell (CD20+) non-Hodgkin lymphoma and mature B-cell acute lymphoblastic luekemia: a report from the Children's Oncology Group. Pediatr Blood Cancer. 2009;52:177-181.
5. Philip T, Hartmann O, Pinkerton R, et al. Curability of relapsed childhood B-cell non-Hodgkin's lymphoma after intensive first line therapy: a report from the Societe Francaise d'Oncologie Pediatrique. Blood. 1993;80:2003-2006.
6. Cairo MS, Sposto R, Perkins SL, et al. Burkitt's and Burkitt-like lymphoma in children and adolescents: a review of the Children's Cancer Group experience. Br J Haematol. 2003;120:660-670.
7. Kobrinsky N, Sposto R, Shah N. Outcomes of treatment of children and adolescents with recurrent non-Hodgkin's lymphoma and Hodgkin's disease with dexamethasone, etoposide, cisplatin, cytarabine, and L-asparaginase, maintence chemotherapy and transplantation: Children's Cancer Group Study CCG-5912. J Clin Oncol. 2001;19:2390-2396.
8. Weaver CH, Birch R, Greco FA, et al. Mobilization and harvesting of peripheral blood stem cells: randomized evaluations of different doses of filgrastim. Br J Haematol. 1998;2:338-347.
9. Halle P, Kanold J, Rapatel C, et al. Granulocyte colony-stimulating factor alone at 20 micrograms/kg vs 10 micrograms/kg for peripheral blood stem cell mobilization in children. Pediatr Transplant 2000;4:285-288.
10. Sevilla J, Gonzalez-Vicent M, Madero F, Madero L, et al. Granulocyte colony-stimulating factor alone at 12 μg/kg twice a day for 4 days for peripheral blood progenitor cell priming in pediatric patients. Bone Marrow Transplant. 2002;30:471-420.
11. Merlin E, Piguet C, Auvirgnon A, et al. The pros and cons of split-dose granulocyte colony-stimulating factor alone rather than a single high dose for hematopoietic cell mobilization in small children (< 15 kg) with solid tumors. Hematologica. 2006;91:1004-1005.
12. To LB, Haylock DN, Simmons PJ, Juttner CA. The biology and clinical uses of blood stem cells. Blood. 1997;89:2233-2258.
13. Korbling M, Flietner T. History of stem cell transplants. In: Gale RP, Juttner C, Henon P, eds. Blood Stem Cell Transplants. New York: Cambridge University Press; 1994:9-19.
14. Narayanasami U, Kanteti R, Morelli J, et al. Randomized trial of filgrastim versus chemotherapy and filgrastim of hematopoietic progenitor cells for rescue in autologous transplantation. Blood. 2001;98:2059-2064.
15. Pusic I, Jiang SY, Landau S, et al. Impact of mobilization and remobilization strategies on achieving sufficient stem cell yields for autologous transplantation. Biol Blood Marrow Transplant. 2008;14:1045-1056.
16. Okada S, Hongo T, Sakaguchi K, et al. Pilot study of ifosfamide/ carboplatin/etoposide (ICE) for peripheral blood stem mobilization in patients with high-risk or relapsed medulloblastoma. Childs Nerv Syst. 2007;23:407-413.
17. Krishnan A, Bhatia S, Slovak ML, et al. Predictors of therapy-related leukemia and myelodysplasia following autologous transplantation for lymphoma: an assessment of risk factors. Blood. 2000;95:1588-1593.
18. Stewart D, Smith C, MacFarland R, Calandra G. Pharmacokinetics and pharmacodynamics of plerixafor in patients with non-Hodgkin lymphoma and multiple myeloma. Biol Blood Marrow Transplant. 2009;15:39-46.
19. Beyer J, Schwella N, Zingsem J, et al. Hematopoietic rescue after high-dose chemotherapy using autologous peripheral blood progenitor cells or bone marrow: a randomized comparison. JClin Oncol. 1995;13:1328-1335.
20. Schmitz N, Dreger P, Linch DC. Randomized trial of filgrastim-mobilized peripheral blood progenitior cell transplantation versus autologous bone-marrow transplant in lymphoma patients. Lancet. 1996;347:353-357.
21. Broxmeyer H, DiPersio J, Flomenberg N. Symposium report. Blood Marrow Transplant Rev. 2005;15:4-10.
22. Voermans C, Kooi ML, Rodenhuis S, et al. In vitro migratory capacity of CD34++ cells is related to hematopoietic recovery after autologous stem cell transplantation. Blood. 2001;97:799-804.
23. Gazitt Y, Liu Q. Plasma levels of SDF-1 and expression of SDF-1 receptor on CD34++ cells in mobilized peripheral blood of non-Hodgkin's lymphoma patients. Stem Cells. 2001;19:37-45.
24. Flomberg N, Devine S, DiPersio J, et al. The use of AMD3100 plus G-CSF for autologous hematopoietic progenitor mobilization is superior to G-CSF alone. Blood. 2005;106:1867-1874.
25. Robertson KA, Pradhan K, Goebel S, et al. Mobilization of peripheral CD34+ stem cells in a heavily pre-treated pediatric medulloblastoma patient. Biol Blood Marrow Transplant. 2006;12:75-76.
26. McGuirk J, Ginn K, Badel K. AMD3100 plus G-CSF use in proven poor mobilizers in a compassionate use protocol. Blood. 2005;106:49a.
27. Calandra, G, McCarty J, McGuirk J, et al. AMD plus G-CSF can successfully mobilize CD34++ cells from non-Hodgkin's lymphoma, Hodgkin's disease, and multiple myeloma patients previously failing mobilization with chemotherapy and/or cytokine treatment: compassionate use data. Bone Marrow Transplant. 2008;41:331-338.
28. Lefrere F, Levy V, Makke J, et al. Successful peripheral blood stem cell harvesting with granulocyte colony-stimulating factor alone after previous mobilization failure. Haematologica. 2004;89:1532-1534.
29. Weaver CH, Tauer K, Zhen B. Second attempts at mobilization of peripheral stem blood stem cells in patients with initial low CD34+ cell yields. J Hematother 1998;3:241-249.
30. Burger JA, Peled A. CXCR4 antagonists: targeting the microenvironment in leukemia and other cancers. Leukemia. 2009;23:43-52.
31. Nervi B, Ramirez P, Rettig M, et al. Chemosensitization of acute myeloid leukemia (AML) following mobilization by the CXCR antagonist AMD3100. Blood. 2009;113:6206-6214.
32. FDA Summary. 12 December 2008. Retrieved 12 April 2009 from: accessdata.fda.gov/drugsatfda docs/nda/2008/022311s000 SumR.pdf:4-5.
33. Hendrix CW, Collier AC, Lederman MM, et al. Safety, pharmacokinetics and antiviral activity of AMD3100, a selective CXCR-4 receptor inhibitor, in HIV-1 infection. J Acquir Immune Defic Syndr. 2004;37:1253-1262.
34. Hendrix CW, Flexner C, MacFarland RT, et al. Pharmacokinetics and safety of AMD-3100, a novel antagonist of the CXCR-4 chemokine receptor in human volunteers. Antimicrob Agents Chemother. 44:1667-1673.
35. FDA Approval Letter. 12 December 2008. Retrieved 12 April 2009 from: www.fda.gov/cder/foi/appletter/2008/022311s000ltr.pdf